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Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey
The current cancer landscape within transitional economies in central and Eastern Europe and the Mediter-
ranean area is not particularly optimistic. Current perceptions are often based on extrapolations from other
countries and regions; and hence the authors collaborated with the South Eastern Europe Oncology Group
(SEEROG) to collect information on cancer registration in Central and Eastern Europe, Israel and Turkey.
Healthcare authorities and specialist oncology centres in 21 countries in the region were contacted for
information on cancer registries in their countries. Based on this information, the authors believe that the
recording and reporting of data on cancer in the region is at an acceptable level. The authors discuss and
compare institution- and population-based registries, and present opinions on elements of an ‘ideal registry’
based on the survey replies and comparisons with other registries. A comparison with the sources used
for GLOBOCAN 2008 illustrates the need for consistent data to be communicated, published and utilised
throughout the region and the oncology community. The authors conclude by considering the potential value
of collaboration between health authorities across the region, as well as between the clinical and epidemio-
logical communities, to ensure that cancer data are consistently collected, verified and made public.
Keywords: cancer epidemiology, Central and Eastern Europe, Israel, Turkey, population-based cancer
registries, institution-based registries.
INTRODUCTION
Cancer remains one of the leading causes of morbidity
and mortality worldwide (Ferlay et al. 2010a, Cancer
Incidence and Mortality Worldwide). In addition to the
Cancer Incidence in Five Continents series of mono-
graphs, which is the reference source for the international
cancer incidence (International Agency for Research on
Cancer 2010, Cancer Incidence in Five Continents), both
GLOBOCAN estimates (Ferlay et al. 2010a, Cancer Inci-
dence and Mortality Worldwide) and the WHO Cancer
Mortality Database (WHO n.d., WHO Mortality Database)
have highlighted the wide variation in incidence and mor-
tality rates across Europe (Ferlay et al. 2010a, Cancer Inci-
dence and Mortality Worldwide; Sant et al. 2009).
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Many factors may play a part in the geographical varia-
tion of cancer incidence and mortality; however, differ-
ences in cancer care account for a substantial proportion
of the higher cancer mortality rates seen in some countries.
There is a wide variation in the quality of cancer care
both globally between developed and developing countries
(International Network for Cancer Treatment and
Research n.d., Cancer in Developing Countries) and within
Europe between the ‘old’ and ‘new’ European Union
(EU) members (Albreht et al. 2008; Gouveia et al. 2008;
Zatonski & Didkowska 2008). Cancer mortality is signifi-
cantly higher in South Eastern and Eastern European coun-
tries, including the new EU countries, and it is a growing
concern that the cancer problem in these states is among
the worst in the region (Levi et al. 2004a,b; Ferlay et al.
2010b; La Vecchia et al. 2010; Znaor et al. 2013).
In order to provide insights into these issues, a working
group of oncologists from countries within Eastern and
Central Europe, Israel and Turkey collaborated with the
South Eastern Europe Oncology Group (SEEROG) to
conduct a comprehensive assessment of cancer registries
in the region. The aim of this review was to understand
better what information is available, how it is reported
and interpreted, and to identify knowledge gaps that could
lead to the misinterpretation of the current cancer burden
in the countries evaluated. One specific goal was to estab-
lish the types of cancer registry in each country.
Population-based registries record all new cases in a
defined population (usually a specific geographical area
such as a country or state); they focus on epidemiology,
and determine cancer patterns and trends over time.
Hospital-based registries have a greater emphasis on
patient care and evaluation of outcomes; data may be
collected by a single hospital or multiple institutions
[National Cancer Institute n.d., Surveillance, Epidemiol-
ogy and End Results (SEER) Training Program Cancer Reg-
istration and Surveillance Modules].
METHODS
The working group of oncologists developed the scope of
the cancer registry review and the strategy for collecting
information. A questionnaire was designed to ascertain
what information was available from cancer registries
across the region. The key aspects of information col-
lected included: type of registry; sources of cancer data;
tumour-specific data items, including cancer type and
treatment; quality control and data reliability; and avail-
ability of registry data within the public domain.
Key oncology centres and healthcare authorities were
identified for each country and were included in the
project. These centres were selected by the authors based
on their reputation and the scope of their activities.
Healthcare authorities included national cancer insti-
tutes, government bodies of health information, health
economics and public health agencies. Questionnaires
were sent by email and regular mail to the identified
participants at each oncology centre and healthcare
authority included in the survey, with regular reminders
to encourage replies. Data from the respondents were
tabulated and reviewed by the working group to enable
the results to be assessed both on an individual and
on a combined level. Further contact was made with indi-
viduals, as required, to resolve any major discrepancies
in descriptions of the registry data between different
respondents from the same country. The main period of
data collection was June to September 2011; after this
period, efforts were devoted to chasing non-responders
and to clarifying ambiguous or incomplete responses.
The data were also compared against reference sources
cited in the most recent version of the GLOBOCAN data-
base (Ferlay et al. 2010a, Cancer Incidence and Mortality
Worldwide).
Ethical committee approval was not required since this
work did not involve human or animal subjects.
RESULTS
A total of 21 countries in Central and Eastern Europe and
the eastern Mediterranean were included in the study. A
total of 41 responses were received out of 77 question-
naires distributed (Table 1). Of these, 28 were received
from specialist oncology centres and 13 from healthcare
authorities. No responses were received from Armenia
and Azerbaijan, but at least one response was received
from all other countries contacted. There was no specific
pattern among non-responders. In general we considered
the response adequate if, after repeated reminders, at least
one response was received from a key oncology centre
and one from a healthcare authority, even though in
some countries, such as Hungary, Romania, Croatia,
Turkey and Serbia, we had identified more than five
potential contributors. In Slovakia, for example, the phy-
sicians responded that one questionnaire was sufficient to
reflect all their responses.
Nature of the registries
All countries who responded to the questionnaire have at
least one procedure for recording cancer incidence and
mortality, although the nature of the processes and the
scope vary considerably (Table 2). In all countries, cancer
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Table 1. List of key oncology centres or healthcare authorities by country who responded to the survey
Country
Key oncology
centre (n)
Healthcare
authority (n) Respondent
Albania 1 1 Ferdinand Jorgoni, MD
Service of Oncology, University Hospital Centre, Tirana
National Cancer Registry, Oncological Institute, Tirana
Ilir Akshia
Service of Oncology, University Hospital Centre, Tirana
Belarus 1 – Aleksey Okeanov, MD
N.N. Alexandrov National Cancer Center of Belarus, Minsk
Bosnia-Herzegovina 1 – Saša Jungic´, MD
Clinic for Internal Oncology, Clinical Hospital Center Banja Luka
Bulgaria – – Bulgarian information in tables 2–4 taken from printed publication of Bulgarian
national cancer registry. Information not obtained from survey replies
Croatia 3 1 Stjepko Pleština, MD, PhD
Department of Oncology, University Hospital Centre, Zagreb
Maja Drežnjak Madunic´, MD
Clinical Hospital Centre (Klinicˇki Bolnicˇki Centar), Osijek
Eduard Vrdoljak, MD, PhD
Clinical Hospital Split, Center of Oncology, Split
Ariana Znaor, MD, PhD
Croatian National Cancer Registry, Croatian National Institute of Public
Health, Zagreb
Czech Republic 1 1 Bohuslav Melichar, MD, PhD
Palacký University Medical School and Teaching Hospital, Olomouc
Tomas Srb
Institute of Health Information and Statistics, Prague
Estonia – 1 Margit Magi, MD
Estonian Cancer Registry, National Institute for Health Development, Tallinn
Hungary 1 1 Laszlo Torday, MD, PhD
Department of Oncotherapy, University of Szeged
Erzsebet Podmaniczky, MD
National Institute of Oncology, Budapest
Israel 1 1 Avishay Sella, MD
Department of Oncology, Assaf Harofeh Centre
Micha Bar-Chana, MD
Israeli Cancer Registry, Jerusalem
Kazakhstan 1 – Suriya Essentayeva, MD
Kazakh Research Institute of Radiology and Oncology, Almaty
Latvia – 1 Anita Maurina, MD
Centre of Health Economics, Riga
Lithuania 3 – Alvydas Cˇesas, MD
Klaipeda University Hospital, Klaipeda
Elona Juozaityte, PhD
Lithuanian University of Health Sciences, Oncology, Institute, Kaunas
Giedre Smailyte, MD
Institute of Oncology, Vilnius University, Vilnius
Macedonia 2 1 Elena Kosevska, MD, PhD
Department for Health Promotion, Analysis and Disease Prevention, Institute
for Public Health, Skopje
Crvenkova Simonida, MD
University Clinic for Radiotherapy and Oncology, Skopje
Petar Stefanovski, MD, PhD
Department of Oncology and Palliative Care, Bitola
Poland 1 2 Piotr Tomczak, MD
University Hospital of Lord’s Transfiguration, Poznan
Ryszard Mezyk
Holycross Cancer Centre (Holycross Cancer Registry), Kielce
Joanna Didkowska
Polish National Cancer Registry, Center of Oncology, Warsaw
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cases are reported to either the national or the local
authorities (Table 2). Local data are usually collected by
the specialist oncology institutes which then send them
to the central healthcare authority registry, if one exists.
In Russia, for example, it has been mandatory since 1953
to report all new cancer cases, and a population-based
national cancer registry was initiated in 1996. Information
is sourced from all healthcare institutions, including
specialist oncology centres, and general health service
information systems that record electronic death certifi-
cation. The data are obtained annually by the two main
cancer institutes (N. N. Blokhin Cancer Research Center,
Moscow and PA Gertsen Oncology Research Institute,
Moscow) in Russia and then sent to the national registry
for registration and reporting purposes.
Poland has 16 regional cancer registries, which, accord-
ing to the survey responses and the published data quality
indicators, can vary in data quality. The regional statistics
are provided to the National Cancer Institute in Warsaw,
which co-ordinates the work of the regional registries,
although it does not produce a compiled national data set.
In Kazakhstan, each oncology centre has its own registry,
and the data from these are compiled by the Ministry of
Health in conjunction with the Kazakh Research Institute
of Radiology and Oncology but, as in Poland, not consoli-
dated into a national cancer data set.
Three countries reported that they have smaller, inde-
pendent registries that supplement information from
national registries. In Hungary, several smaller, tumour-
specific registries exist, including a hepatocellular carci-
noma (HCC) and a gastrointestinal stromal tumour (GIST)
registry. These registries are completely independent of the
National Cancer Registry, and there is no data exchange
between them (Table 2). In the Czech Republic, the
national registry includes comprehensive data on all cancer
types, but there are also several independent registries
Table 1. Continued
Country
Key oncology
centre (n)
Healthcare
authority (n) Respondent
Romania 3 – Dana Lucia Stanculeanu, MD
Oncology Institute ‘Prof. Dr. Al. Trestioreanu’, Bucharest
Mircea Dediu, MD
Institute of Oncology, Bucharest
Delia Mateescu, MD
Queen Mary Hospital Bucharest, Bucharest
Russia 2 – Galina Kharkevich, MD, PhD
Federal State Budgetary Institution ‘N.N.Blokhin Russian Cancer Research
Center’ under the Russian Academy of Medical Sciences, Moscow
Valeriy Ivanovich Chissov, MD
Moscow PA Gertsen Research Oncological Institute, Moscow
Serbia 3 – Ana Jovicevic, MD
Institute for Oncology and Radiology of Serbia, Belgrade
Marica Miladinov-Mikov, MD
Oncology Institute of Vojvodina, Sremska Kamenica
Jasmina Nedovic´, MD
Clinical Center Kragujevac, Kragujevac
Slovakia 1 – Jozef Mardiak, MD
National Cancer Institute, Bratislava
Slovenia – 2 Tina Žagar, PhD
Epidemiology and Cancer Registry, Institute of Oncology Ljubljana, Ljubljana
Maja Primic Žakelj, MD, PhD
Epidemiology and Cancer Registry, Head Institute of Oncology Ljubljana,
Ljubljana
Turkey 2 – Mahmut Gumus, MD
Kartal Dr. Lutfi Kirdar Research and Training Hospital, Istanbul
Suayib Yalcin, MD
Hacettepe University Institute of Oncology, Ankara
Ukraine 1 1 Yaroslav Shparyk, MD
Lviv Cancer Center, Lviv
Andrey Gaisenko, MD
National Cancer Institute, Kyiv
Zoya Fedorenko, MD
National Cancer Institute, Kyiv
Total (41) 28 13
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Table 2. Type of country registries and comparison with source of data used by GLOBOCAN 2008 for each country
Country
Type of registry in each country
Source of data used by GLOBOCAN 2008 for each country
Population-
based
Specialist
centres National Regional
Hospital-
specific
Albania ✓ ✓ ✓ National incidence modelled from estimated mortality data using
incidence : mortality ratios obtained by aggregation of cancer registry
data from Bulgaria and Central Serbia.
Estimated mortality by sex was partitioned by site using national mortality
data (including Bulgaria and Greece)
Belarus ✓ ✓ National incidence rates (1978–2002) projected to 2008 population.
National mortality rates for most tumour types (1989–2003) projected to
2004–2006 and applied to 2008 population
Bosnia-
Herzegovina
✓ ✓ ✓ National incidence and mortality rates estimated as average of estimates
from Albania, Macedonia, Serbia, Croatia and Slovenia
Bulgaria ✓ ✓ National incidence and mortality for 2008
Croatia ✓ ✓ National incidence (1998–2007) projected to 2008 population; recorded
mortality rates for 2008
Czech
Republic
✓ ✓* National incidence rates (1998–2007) projected to 2008 population; recorded
mortality rates for 2008
Estonia ✓ ✓ National incidence rates (1984–2003) projected to 2008 population; recorded
mortality rates for 2008
Hungary ✓ ✓† National incidence estimated from mortality data modelled using
incidence : mortality ratios obtained by aggregation of cancer registry
data from Czech Republic and Slovakia; recorded mortality rates for 2008
Israel ✓ ✓ National incidence rates (1983–2002) projected to 2008 population
National mortality rates (1986–2005) projected to 2008 population
Kazakhstan ✓ ✓ National incidence and mortality rates estimated from estimated mortality
data modelled using incidence : mortality ratios obtained by aggregation
of cancer registry data from South-Central Asia: India (Mumbai, Chennai,
Barshi, Karunagappally) and Iran (Ardabil province)
Latvia ✓ ✓ National incidence rates (1984–2003) projected to 2008 population; recorded
mortality rates for 2008
Lithuania ✓ ✓ National incidence rates (1986–2005) projected to 2008 population; recorded
mortality rates for 2008
Macedonia ✓ ✓ ✓ National incidence rates estimated from mortality data modelled using
incidence : mortality ratios obtained by aggregation of cancer registry
data from Bulgaria and Central Serbia; for most cancers, national
mortality rates (1991–2003) corrected for 8% under-reporting and
projected to 2008
Poland ✓ ✓ ✓ National incidence rates estimated from mortality data modelled using
incidence : mortality ratios obtained by aggregation of cancer registry
data from four regional registries (Cracow, Kielce, Podkarpacki and
Warsaw); recorded mortality rates for 2008
Romania ✓ ✓ ✓ National incidence rates estimated from mortality data modelled using
incidence : mortality ratios obtained by aggregation of cancer registry
data from Bulgaria, Slovakia and Romania (Cluj cancer registry); recorded
mortality rates for 2008
Russia ✓ ✓ ✓ ✓ ✓ National incidence and mortality for 2008
Serbia ✓ ✓ ✓ ✓ National incidence was estimated from estimated mortality data modelled
using incidence : mortality ratios obtained by aggregation of cancer
registry data from Serbian regional cancer registries; recorded mortality
rates for 2008 corrected for 15% under-reporting
Slovakia ✓ ✓ National incidence rates (1986–2005) projected to 2008 population; national
mortality rates (1991–2005) projected to 2008 population
Slovenia ✓ ✓ ✓ National incidence rates (2000–2007) projected to 2008 population; recorded
national mortality rates for 2008
Turkey ✓ ✓‡ No national data available
Incidence rates estimated as weighted average of those observed in Iran
(Ardabil province, 2004–2006) for East and South-East regions (20%
of the Turkish population); simple mean of Antalya Cancer Registry
(1998–2002) and Izmir Cancer Registry (1998–2002); mortality rates
estimated from incidence rates and cancer site-specific survival,
estimated by GDP method§
Ukraine ✓ ✓ ✓ National incidence rates for 2008; mortality rates for some cancers from
national data; others calculated from Ukrainian regional cancer registries
*National registry complemented by independent patient registries related to specific treatments with targeted therapies.
†In addition to the national registry a number of independent, small, tumour-specific registries exist.
‡Specific cancer centres and regional cancer working groups have additional specific disease-oriented registries.
§GDP method of estimating cancer mortality is based on the estimated relationship between cancer-specific 5-year relative survival and country-specific
GDP per capita.
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related to specific treatments with the new targeted thera-
pies, such as those for renal cell carcinoma and GIST. In
Turkey, specific cancer centres, such as those in Antalya
and Izmir, have population-based cancer registries.
The situation in Romania is currently undergoing sig-
nificant change, with the initiation of a national cancer
registry anticipated in 2013. The registry will build upon
experience of an existing regional registry from a specialist
centre (Cluj Oncology Institute), which has undergone
recent upgrades to ensure it is capable of the wider role of
leadership of national cancer registration.
Sources of the cancer data
Data are obtained mostly from patients’ hospital or
primary care notifications and death certificates, often
supplemented with pathology reports and hospital dis-
charge data. Typically, a country’s national cancer registry
receives notification of every cancer case from the regional
healthcare administration or the medical institution
responsible for the patient. For the smaller, independent,
disease-specific registries, data are provided voluntarily by
the treating physicians. Thus, although these registries
may be more exhaustive in their data collection due to
more detailed clinical research forms being used, they are
rarely able to generate reliable incidence data.
Reporting of cases is usually the responsibility of the
lead oncology physician or a trained nurse. In contrast,
administrators or statistics clerks undertake reporting in
Serbia and Albania. However, survey responses from Israel
and Romania indicated that the overall responsibility for
reporting data lies with the head of the oncology institute
or registry, with the assistance of administrative staff. In
Russia, it is the head of the statistical department of each
healthcare institution who is responsible for the reliabil-
ity of these data. Polish respondents indicated that, in line
with standard practice, notification of a cancer diagnosis
to a regional cancer registry is actively followed up and
audited by registry staff, who visit each co-operating hos-
pital annually to complete any missing information for all
cases.
Type of cancer data collected
All countries surveyed indicated that they have a basic
requirement to collect data on tumour type and stage
at diagnosis, with histology details to differing degrees
(Table 3). The registries in almost all countries include, as
a minimum, incidence rates by cancer site, sex and age
group. Data for a comprehensive range of solid tumours
are available from all countries, with topography coding
by the International Statistical Classification of Diseases
and Related Health Problems 10th Revision (ICD-10). A
large number of countries also report survival estimates
related to age and stage at diagnosis, and gender (Table 3).
Data on cancer treatment
All countries except Kazakhstan record some informa-
tion on treatments, although several countries indicated
that this is at a basic, minimal level (Table 3). Treatment
is recorded as surgical, radiological or systemic (chemo-
therapy, hormone treatment, immunotherapy, targeted
therapies); only the Czech Republic collects detailed infor-
mation on both treatment method and intention (e.g. adju-
vant or neoadjuvant).
The Czech Republic also has several specialist targeted
therapy registries and listings by individual drugs and
drug class (Table 3). This is likely to be the situation in
other countries, but was not reported by other respond-
ents. The targeted therapy registries are independent
of the main cancer registries and are run by individual
institutions. Thus, the data on them may not be as repre-
sentative of the whole population as in the main cancer
registry. In Russia, data on all treatment modalities,
including targeted therapy, are available within the regis-
tries of the individual institutions.
Quality control of data and reliability
Most respondents stated that their registries carry out
internal audits of their data. Most comply with Interna-
tional Agency for Research on Cancer (IARC) guidelines
(International Agency for Research on Cancer 1991.
Cancer Registration: Principles and Methods IARC Scien-
tific Publication No. 95). Part of the validation process, as
in Bulgaria, for example, involves analysing the extent
to which the national registry conforms to international
guidelines and standards for cancer registration.
Subjective opinions provided by respondents to the
survey indicated that the data submitted to their registries
could be more reliable.
Availability of data in the public domain
The majority of specialist oncology centres included in
this study encourage physicians to publish cancer epide-
miology data at national, regional or international con-
gresses, or in journals (Table 4). The most widely used
publication vehicle is government-sponsored publications
in print and on the worldwide web (Table 4).
Registries are typically updated at least once per year,
but it can take up to 2 years to analyse the data fully;
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hence publication is often around 2 years behind the
current date.
DISCUSSION
Data available
Epidemiological information is at the core of knowledge
in medicine, especially in the field of cancer, and there
is an expectation that improvements in the data available
will have a positive influence on the ability to target
resources effectively (Levi et al. 2001, 2003, 2004b; Parkin
et al. 2001; Antunes et al. 2003; Boyle et al. 2003; Janssens
et al. 2003; Quinn et al. 2003; Boyle 2004; Znaor & Bray
2012). It is anticipated that using all available knowledge
could enhance the success and enable monitoring and
evaluation of cancer prevention and treatment in the tran-
sitional countries discussed here compared with the origi-
nal 15 EU countries (Boyle et al. 2003).
Based on the information collected, the authors believe
that the recording and reporting of data on cancers is at an
acceptable level in most countries across the region. The
authors agree that all cancer registries throughout the
region should comply with international standards and
guidelines provided by the European Network of Cancer
Registries and the International Association of Cancer
Registries (IACR) (European Network of Cancer Registries
n.d.; International Agency for Research on Cancer 1991,
Cancer Registration: Principles and Methods IARC Scien-
tific Publication No. 95; International Association of
Cancer Registries n.d., Resources for Cancer Registration).
Ideally, this would also be combined with treatment data,
which would allow for ongoing assessment of the real
impact of newer, more expensive cancer therapies.
Higher incidence rates compared with neighbouring
countries should encourage authorities to explore risk
factors responsible for these variations; higher mortality
rates in South Eastern compared with North Western
European countries (Znaor et al. 2013) should lead to
evaluation of possible causes and a review of cancer man-
agement and treatment, as well as the implementation of
screening programmes.
Awareness of the quality of reported mortality and
incidence data is critical for reliable interpretation of the
data and subsequent decisions. A round-table or consen-
sus meeting where representatives of health authorities,
cancer registries and key oncology centres would debate
and comment on their national data, and have the oppor-
tunity to exchange information with neighbouring coun-
tries, could contribute to informed decision-making and
eventually lead to measures improving the overall quality
of the information. Ideally, dedicated staff would be
available to collect and analyse cancer information but
economic constraints may inhibit this. Involving the
pharmaceutical industry in such a process on a national,
regional or European level may ease the economic burden.
Types of registry
A further consideration is whether it is necessary to
have both institution-specific and national/regional
population-based cancer registries. This might seem to be
duplication, but there are theoretical reasons for having
both types of registries. National population-based regis-
tries capture and present key epidemiological data such
as mortality and incidence rates. Institution-based regis-
tries, typically from specialist centres, are more likely to
include detailed case information including tumour
size, grade, molecular markers present, treatments and
clinical outcomes, which can provide valuable insights
into local cancer patterns and treatment successes. The
authors believe that a complementary system has many
advantages, as well as some inherent risks if not executed
properly.
One option to capitalise on the value of institution-based
data collection and at the same time avoid the inherent
risks of duplication of effort would be to collect data only at
an institutional level, with selected data, carefully pre-
defined by specific rules, transferred to a central registry.
An alternative would be to submit all primary cancer data
directly to a central registry, with a possibility for linkage
with cancer treatment data in the future.
Comparison of country registries with the GLOBOCAN
2008 data sources
At least one registry from each country that responded to
the survey either contributes data to, or is a member of,
the IACR (International Association of Cancer Registries
n.d.). GLOBOCAN cancer incidence estimates are avail-
able for all countries and are based on the most recent data
available at the IARC, on information publically available
on the internet or directly from local sources (Ferlay et al.
2010a, Cancer Incidence and Mortality Worldwide). The
incidence data used must fulfil certain standards, and pass
quality checks both locally and by the IACR. If such data
are not available, other sources are used to estimate inci-
dence, as described in the GLOBOCAN methods (Ferlay
et al. 2010a, Cancer Incidence and Mortality Worldwide).
Inconsistencies were therefore observed between some
source data used by GLOBOCAN and the information
that survey respondents indicated was available in their
countries (Table 2).
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Suggestions for the future use of cancer registry
data in oncology
The authors believe that the future role of a cancer regis-
try will expand beyond a focus on epidemiology. A registry
should be multi-purpose, and include reliable data on
treatments and outcomes for cancer patients, including
survival data, as well as survivorship data. In addition to
the well-established uses of cancer registries in epidemio-
logical research and as the key tool for evaluation and
monitoring of preventive programmes in the popula-
tion, they could include disease-specific outcomes, enable
evaluation of different treatment modalities (such as
radiation therapy, surgical and medical treatments) and
generate data on healthcare resource utilisation, which
can be used in developing cost-effectiveness models. For
example, data from the British Columbia Cancer Agency
have been used in cost-effectiveness analyses for imatinib
and trastuzumab (Mabasa et al. 2008; Hedden et al. 2012).
Registry databases could be used to identify potential
patients for inclusion in clinical trials, as well providing
a tool to identify subsets of patients who do or do not
benefit from specific treatments. For example, an analysis
of the Surveillance, Epidemiology and End Results (SEER)
database showed that the benefits of adjuvant radiation for
gastric cancer were stage-dependent (Coburn et al. 2008).
Treatment- or drug-specific registries have been set up in
other therapeutic areas when novel drugs have been intro-
duced, such as anti-tumour necrosis factor-α treatment
registries in the field of rheumatoid arthritis (Hetland
2005; Tubach et al. 2005; Watson et al. 2005; Neovius
et al. 2011), but in oncology, few drug- or cancer type-
specific registries exist. Newly introduced, personalised
treatments, such as targeted agents for renal cell carcinoma
and non-small cell lung cancer, and immune system acti-
vators for melanoma, represent important investments for
health authorities and as yet little is known of their clinical
impact. Specific drug- or cancer-type registries, ideally at a
national level, would be a valuable source of information to
monitor the clinical benefit of these novel treatments, and
assist in assessing the advantages of reimbursing these
drugs. For certain very rare types of cancer, or cancers with
specific driver mutations (which may be the future of
oncology), it will probably be necessary to organise regional
or global registries in order to manage these patients better
and to facilitate research on these populations.
The comprehensive nature of the information that
can be obtained through a national cancer registry is illus-
trated by a model from the Nordic countries. Typically,
all inhabitants of these countries have a national personal
identification number through which their entry to
healthcare registries for various diseases can be aligned
with comprehensive data on all aspects of healthcare
relating to the condition. The RENal COMParison
(RENCOMP) study in Sweden, for example, used data
from the National Cancer Register, National Patient Reg-
ister and the Swedish Prescribed Drug Register (from 2005
onwards) to assess trends in treatment and survival of
renal cell carcinoma. They showed, on a national level,
that the introduction of tyrosine kinase inhibitors was
associated with improved overall survival of patients with
metastatic renal cell carcinoma (Harmenberg et al. 2012).
Communication of registry data
Collecting and analysing the data is one part of the process,
but communication of the information is equally impor-
tant. One of the widest areas of inter-country variation
revealed by this survey is the publication and availability of
data from both population-based and institutional regis-
tries. If the true, complementary value of population-based
and institution-based registries is to be realised, then wider
publication and publicity should be actively encouraged.
Effective communication is an important responsibility
for all institutions, national and global bodies to ensure
that data are truly representative for each country and
cancer sub-specialty. In situations such as those outlined
here, it is understandable that medical specialists may be
confused as to what to consider as a true representation
of their country’s cancer burden. To this effect, the
GLOBOCAN website does contain a cautionary note that
the data it represents may not always correspond to
recorded data which are now becoming available (Ferlay
et al. 2010a, Cancer Incidence and Mortality Worldwide).
It must be acknowledged that a questionnaire-based
survey has some weaknesses which limit the conclusions
that can be drawn. For example, the response rate was
considerably lower from healthcare authorities than from
oncology institutions and the quality of the data was not
further validated. Detailed and structured interviews with
key physicians and healthcare authority leaders, as well as
involving the cancer registry community to follow up on
survey responses, and provision of data quality indicators
rather than isolated checks of inconsistencies, could
provide further insights.
CONCLUSION
Individual country health authorities should encourage
cancer registration and base their decisions for cancer
healthcare on robust, nationally owned and up-to-date
epidemiological data. The potential value of collaboration
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between health authorities across the region to ensure
that their data are consistently collected, verified and
made public should be explored.
ACKNOWLEDGEMENTS
The authors thank all of the respondents who contributed
their information to the survey which formed the basis of
this manuscript. They also thank Tonkica Boban for her
assistance in collecting responses.
DISCLOSURE
The authors designed the survey and analysed the
data. Editorial support in the form of collation of survey
responses, preparation of draft outline and manuscript
first draft, assembling tables and figures and collating
author comments was provided by Mark Edmondson and
Christine Drewienkiewicz (Choice Healthcare Solutions,
London, UK) and was funded by Pfizer Oncology. The
study was sponsored by Pfizer.
REFERENCES
Albreht T., McKee M., Alexe D.M.,
Coleman M.P. & Martin-Moreno J.M.
(2008) Making progress against cancer
in Europe in 2008. European Journal of
Cancer 44, 1451–1456.
Antunes J.L., Toporcov T.N. & de Andrade
F.P. (2003) Trends and patterns of cancer
mortality in European countries. Euro-
pean Journal of Cancer Prevention 12,
367–372.
Boyle P. (2004) Testicular cancer: the chal-
lenge for cancer control. The Lancet
Oncology 5, 56–61.
Boyle P., Autier P., Bartelink H., Baselga
J., Boffetta P., Burn J., Burns H.J.,
Christensen L., Denis L., Dicato M.,
Diehl V., Doll R., Franceschi S., Gillis
C.R., Gray N., Griciute L., Hackshaw A.,
Kasler M., Kogevinas M., Kvinnsland
S., La Vecchia C., Levi F., McVie J.G.,
Maisonneuve P., Martin-Moreno J.M.,
Bishop J.N., Oleari F., Perrin P., Quinn
M., Richards M., Ringborg U., Scully C.,
Siracka E., Storm H., Tubiana M., Tursz
T., Veronesi U., Wald N., Weber W.,
Zaridze D.G., Zatonski W. & zur Hausen
H. (2003) European Code Against Cancer
and scientific justification: third version
(2003). Annals of Oncology 14, 973–
1005.
Coburn N.G., Govindarajan A., Law C.H.,
Guller U., Kiss A., Ringash J., Swallow
C.J. & Baxter N.N. (2008) Stage-specific
effect of adjuvant therapy following
gastric cancer resection: a population-
based analysis of 4041 patients. Annals of
Surgical Oncology 15, 500–507.
European Network of Cancer Registries
(n.d.) [Online]. Available at: http://www
.encr.eu/ [accessed 22 November 2012].
Ferlay J., Shin H.R., Bray F., Forman D.,
Mathers C. & Parkin D.M. (2010a)
GLOBOCAN 2008 v2.0, Cancer Incidence
and Mortality Worldwide: IARC Cancer-
Base No. 10 [Internet]. Lyon, France: Inter-
national Agency for Research on Cancer;
2010 [Online]. Available at: http://
globocan.iarc.fr [accessed 12 November
2012].
Ferlay J., Parkin D.M. & Steliarova-Foucher
E. (2010b) Estimates of cancer incidence
and mortality in Europe in 2008. Euro-
pean Journal of Cancer 46, 765–781.
Gouveia J., Coleman M.P., Haward R.,
Zanetti R., Hakama M., Borras J.M.,
Primic-Zakelj M., de Koning H.J. &
Travado L. (2008) Improving cancer
control in the European Union: conclu-
sions from the Lisbon round-table under
the Portuguese EU Presidency, 2007.
European Journal of Cancer 44, 1457–
1462.
Harmenberg U., Lundstam S., Wahlgren T.,
Kowalski J., Jakobsson M., Sandin R.,
Ljungberg B. & Sandström P. (2012)
Treatment and overall survival (OS)
in metastatic renal cell carcinoma
(mRCC): a Swedish population-based
study (2000–2008). ASCO 2012 Genitou-
rinary Cancers Symposium.
Hedden L., O’Reilly S., Lohrisch C., Chia
S., Speers C., Kovacic L., Taylor S. &
Peacock S. (2012) Assessing the real-
world cost-effectiveness of adjuvant
trastuzumab in HER-2/neu positive
breast cancer. The Oncologist 17, 164–
171.
Hetland M.L. (2005) DANBIO: a nation-
wide registry of biological therapies in
Denmark. Clinical and Experimental
Rheumatology 23, S205–S207.
International Agency for Research on
Cancer (1991) Cancer Registration: Prin-
ciples and Methods IARC Scientific Pub-
lication No. 95 [Online]. Available at:
http://www.iarc.fr/print.php?&uri=/en/
publications/pdfs-online/epi/sp95/
index.php [accessed 1 March 2013].
International Agency for Research on
Cancer (2010) Cancer Incidence in Five
Continents [Online]. Available at: http://
ci5.iarc.fr/CI5i-ix/ci5i-ix.htm [accessed 1
March 2013].
International Association of Cancer Regis-
tries (n.d.) Resources for Cancer Registra-
tion [Online]. Available at: http://www
.iacr.com.fr/ [accessed 1 March 2013].
International Network for Cancer Treat-
ment and Research (n.d.) Cancer in Devel-
oping Countries [Online]. Available at:
http://www.inctr.org/about-inctr/cancer
-in-developing-countries/ [accessed 1
March 2013].
Janssens J.P., Giacosa A. & Stockbrugger R.
(2003) The European Community expan-
sion and cancer burden. European Journal
of Cancer Prevention 12, 353–354.
La Vecchia C., Bosetti C., Lucchini F.,
Bertuccio P., Negri E., Boyle P. & Levi F.
(2010) Cancer mortality in Europe, 2000–
2004, and an overview of trends since
1975. Annals of Oncology 21, 1323–1360.
Levi F., Lucchini F., Franceschi S., Negri E.
& La Vecchia C. (2001) Inequalities in
health in Europe. British Medical Journal
322, 798.
Levi F., Lucchini F., Boyle P., Negri E. &
La Vecchia C. (2003) Testicular cancer
mortality in Eastern Europe. Interna-
tional Journal of Cancer 105, 574.
Levi F., Lucchini F., Negri E. & La Vecchia
C. (2004a) Trends in mortality from
major cancers in the European Union,
including acceding countries, in 2004.
Cancer 101, 2843–2850.
Levi F., Lucchini F., Negri E., Zatonski W.,
Boyle P. & La Vecchia C. (2004b) Trends
in cancer mortality in the European
Union and accession countries, 1980–
2000. Annals of Oncology 15, 1425–1431.
Mabasa V.H., Taylor S.C., Chu C.C.,
Moravan V., Johnston K., Peacock S. &
Knowling M. (2008) Verification of
imatinib cost-effectiveness in advanced
gastrointestinal stromal tumor in British
Columbia (VINCE-BC study). Journal of
Oncology Pharmacy Practice 14, 105–
112.
National Cancer Institute (n.d.) Surveil-
lance, Epidemiology and End Results
(SEER) Training Program Cancer
Registration and Surveillance Modules
[Online]. Available at: http://training
.seer.cancer.gov/modules_reg_surv.html
[accessed 1 March 2013].
Neovius M., Simard J.F., Askling J. &
ARTIS study group (2011) Nationwide
prevalence of rheumatoid arthritis and
penetration of disease-modifying drugs in
Sweden. Annals of the Rheumatic
Diseases 70, 624–629.
Cancer surveillance review
109© 2013 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
Parkin D.M., Bray F., Ferlay J. & Pisani
P. (2001) Estimating the world cancer
burden: GLOBOCAN 2000. Inter-
national Journal of Cancer 94, 153–
156.
Quinn M.J., d’Onofrio A., Moller B.,
Black R., Martinez-Garcia C., Moller H.,
Rahu M., Robertson C., Schouten L.J.,
La Vecchia C. & Boyle P. (2003) Cancer
mortality trends in the EU and acceding
countries up to 2015. Annals of Oncology
14, 1148–1152.
Sant M., Allemani C., Santaquilani M.,
Knijn A., Marchesi F., Capocaccia R. &
EUROCARE Working Group (2009)
EUROCARE-4. Survival of cancer
patients diagnosed in 1995–1999. Results
and commentary. European Journal of
Cancer 45, 931–991.
Tubach F., Salmon-Ceron D., Ravaud P.,
Mariette X. & Ratio Study Group (2005)
The RATIO observatory: French registry
of opportunistic infections, severe bacte-
rial infections, and lymphomas com-
plicating anti-TnFalpha therapy. Joint,
Bone, Spine : Revue du Rhumatisme 72,
456–460.
Watson K., Symmons D., Griffiths I. &
Silman A. (2005) The British Society for
Rheumatology biologics register. Annals
of the Rheumatic Diseases 64 (Suppl. 4),
iv42–iv43.
WHO (n.d.) WHO Mortality Database
[Online]. Available at: http://www.who
.int/healthinfo/morttables/en/ [accessed
1 March 2013].
Zatonski W. & Didkowska J. (2008) Closing
the gap: cancer in Central and Eastern
Europe (CEE). European Journal of
Cancer 44, 1425–1437.
Znaor A. & Bray F. (2012) Thirty year trends
in testicular cancer mortality in Europe:
gaps persist between the East and West.
Acta Oncologica (Stockholm, Sweden)
51, 956–958.
Znaor A., van den Hurk C., Primic-Zakelj
M., Agius D., Coza D., Demetriou A.,
Dimitrova N., Eser S., Karakilinc H.,
Zivkovic S., Bray F. & Coebergh J.W.
(2013) Cancer incidence and mortality
patterns in South Eastern Europe in the
last decade: gaps persist compared with
the rest of Europe. European Journal
of Cancer (Oxford, England: 1990) 49,
1683–1691.
VRDOLJAK ET AL.
110 © 2013 The Authors. European Journal of Cancer Care Published by John Wiley & Sons Ltd.
